Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Cohort Study Assessing the Immune-Related Adverse Events in Patients Receiving the Anti-PD-1/PD-L1 Agents

Next Previous
Trial Profile

A Prospective Cohort Study Assessing the Immune-Related Adverse Events in Patients Receiving the Anti-PD-1/PD-L1 Agents

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer
  • Focus Adverse reactions

Most Recent Events

  • 26 Jun 2020 New trial record
  • 06 Jun 2020 Interim results (N=52), presented at the 21st Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top